Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab autoinjector vs vial bioavailability in healthy volunteers
NCT06438263Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rocatinlimab in atopic dermatitis (AD) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration of Rocatinlimab at 112 days, Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration at 112 days and 1 more. Started Aug 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06438263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438263.